Pfizer succeeds in Inlyta NICE appeal

Save

NICE said: "Following the appeal process, NICE issued an updated scope and matrix to include sunitinib and pazopanib as comparators in addition to best supportive care for the post-cytokine sub-group, and the manufacturer of axitinib submitted more…